ORIC Pharmaceuticals, Inc.
ORIC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,107 | $1,032 | $0 | $0 |
| Gross Profit | -$1,107 | -$1,032 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $114,072 | $85,172 | $61,680 | $56,858 |
| G&A Expenses | $28,823 | $25,608 | $25,087 | $22,013 |
| SG&A Expenses | $28,823 | $25,608 | $25,087 | $22,013 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,107 | -$1,032 | $5,000 | $0 |
| Operating Expenses | $141,788 | $109,748 | $91,767 | $78,871 |
| Operating Income | -$142,895 | -$110,780 | -$91,767 | -$78,871 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15,048 | $10,083 | $2,645 | $156 |
| Pre-Tax Income | -$127,847 | -$100,697 | -$89,122 | -$78,715 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127,847 | -$100,697 | -$89,122 | -$78,715 |
| % Margin | – | – | – | – |
| EPS | -1.83 | -1.96 | -2.25 | -2.07 |
| % Growth | 6.6% | 12.9% | -8.7% | – |
| EPS Diluted | -1.83 | -1.96 | -2.25 | -2.07 |
| Weighted Avg Shares Out | 69,728 | 51,450 | 39,655 | 37,954 |
| Weighted Avg Shares Out Dil | 69,728 | 51,451 | 39,655 | 37,954 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10,083 | $2,645 | $141 |
| Interest Expense | $0 | $0 | $2,645 | $0 |
| Depreciation & Amortization | $1,107 | $1,032 | $966 | $897 |
| EBITDA | -$126,740 | -$109,748 | -$85,801 | -$77,974 |
| % Margin | – | – | – | – |